Categorization of voice disorders with six perceptual dimensions.

To obtain a perceptual reference for acoustic feature selection, 94 male and 124 female voices were categorized using the ratings of 6 clinicians on visual analog scales for pathology, roughness, breathiness, strain, asthenia, and pitch. Partial correlations showed that breathiness and roughness were the main determinants of pathology. The six-dimensional ratings (the six median scores for each voice) were categorized with the aid of the Sammon map and the self-organizing map. The five categories created differed with respect to the breathiness/roughness ratio and the degree of pathology.

Voice reactions to histamine inhalation in asthma.

Susceptibility to voice reactions during a histamine provocation test was studied in 21 asthmatics and 21 healthy subjects. Speech samples were recorded before, and 5 and 15 min after histamine inhalation, and the samples were rated by six speech pathologists. Deterioration of voice quality occurred in 2/12 asthmatic men and in 3/9 asthmatic women within 5 min after histamine inhalation; no change was observed between 5 and 15 min. Voice reactions were not related to the degree of bronchial obstruction: the subjects with the most pronounced decrease in peak expiratory flow (PEF) (60-61% in three subjects) did not develop voice reactions, and PEF did not decrease in one subject with voice reactions. No voice reactions were observed in the healthy subjects.

A rapid dosimetric method with controlled tidal breathing for histamine challenge. Repeatability and distribution of bronchial reactivity in a clinical material.

A rapid dosimetric method with controlled tidal breathing for histamine challenge was evaluated by assessment of its repeatability, by comparing to a present nondosimetric standard method, and by application to adult patients with recent asthma (n = 31), chronic asthma (n = 33), chronic cough (n = 71) or chronic rhinitis (n = 41) and to healthy controls (n = 31). An automatic inhalation-synchronized dosimetric jet nebulizer with a known lung deposition of the aerosol was used to administer histamine and to control breathing. The non-cumulative doses of histamine diphosphate were 0.025, 0.1, 0.4 and 1.6 mg, administered during 0.4 s following tidal inspiration of 100 ml of air. The test procedure required 1 inhalation of histamine 4 mg/ml and followed by 1, 4 and 16 inhalations of histamine 16 mg/ml from the device, and its duration was about 30 minutes. The intraindividual correlation coefficient of the histamine dose causing a reduction of 15 percent in FEV1 (PD15FEV1) on 2 consecutive days in 14 asthmatic subjects was 0.937; the standard error of the single determination was 13 percent of the mean PD15 FEV1. A PD15FEV1 value below 0.4 mg was found only in asthmatic subjects; in chronic asthma, below 0.5 mg; in recent asthma, between 0.1 mg and 1.6 mg or more. In patients with chronic cough and chronic rhinitis, 20 and 32 percent, respectively, the PD15FEV1 values between 0.4 and 1.6 mg, the other patients in these groups were non-responsive. In all healthy control subjects, the PD15FEV1 was over 1.0 mg, 80 percent of them were nonresponsive to the maximum 1.6 mg dose. This new test allows rapid, accurate, and quantitative assessment of bronchial responsiveness to histamine.

Evaluation of a new spacer device for drug inhalation.

We have studied the efficacy and acceptability of a new inhalation spacer device. The functional principle of the device, differing from that of conventional spacers, is based on evaporation of the propellant during circular movement of the aerosol in a small spherical chamber. We assessed the bronchodilating effect of salbutamol (Salbuvent) inhaled with the new spacer (Rondo) compared with salbutamol (Ventoline) inhaled with the spacer Volumatic and with salbutamol (Salbuvent) inhaled with a conventional metered dose actuator using a double-blind cross-over arrangement. Fifteen asthmatic patients were treated over a period of 4 weeks. They used each of the three different devices for 2-3 days every week. Peak expiratory flow rates were recorded every morning after one and after two puffs of the study drugs. The bronchodilator responses to the three treatments were similar within narrow ranges of estimate. By visual analogue scale assessment the new spacer was significantly easier to handle (P < 0.05) and more convenient to carry around (P < 0.01) than Volumatic.

Nocturnal oxygen saturation and body movement in asthmatics treated with controlled-release preparations of theophylline or terbutaline.

Nine adult asthmatics with a history of nocturnal symptoms and with morning dips in peak expiratory flow (PEF) were treated for 10-14 days with 24-h controlled-release preparation of theophylline (Th), or a controlled-release preparation of terbutaline (Te), in a double-blind cross-over experiment. During treatment with 450-900 mg Th in the evening morning, plasma drug levels ranged from 53-95 (mean 73) mumol/l. The Te dose was 7.5 mg twice daily. Morning PEF values during Th (mean 338 l.min-1) and Te (316 l.min-1) were not significantly different. There were no significant differences between the treatments in average nocturnal oximetric O2 saturation (91.9% during Th and 91.0% during Te), or the amount of nocturnal body movement, recorded with a static charge sensitive bed (total number of movements 146 during Th and 120 during Te). No difference between the treatments was seen with respect to assessment by the subjects of sleep quality, which was considered fair or good. The findings suggest that in moderately severe asthma, nocturnal oxygenation and sleep quality were similar during the two treatments.

Psychosocial effects of continuous oxygen therapy in hypoxaemic chronic obstructive pulmonary disease patients.

Twenty six hypoxaemic patients with severe and stable chronic obstructive pulmonary disease (COPD) were treated with continuous domiciliary oxygen for a six month period. The patients were evaluated 1, 3 and 6 months after the start of oxygen therapy. In addition to blood gas analysis, 15 coping skills were evaluated by the patient and by the nurse, who also rated the general activity of the patients. Depression was measured by Beck Depression Inventory (BDI) at the start of the trial and after six months' oxygen therapy. The general psychosocial response was meagre; no significant changes were observed in any psychosocial measures. The response was slightly better in younger and less hypoxaemic patients. We conclude that the psychosocial response to oxygen therapy in severely hypoxaemic COPD patients is limited.

Radiation pneumonitis and fibrosis following split-course radiation therapy for lung cancer. A radiologic and physiologic study.

Radiographic signs of radiation pneumonitis and fibrosis were assessed and pulmonary function monitored in lung cancer patients after two different split-course radiation therapy schedules, one with a rest interval of 3 weeks and the other with a rest interval of 5 weeks, the total radiation dose being the same in both treatments (55 Gy/20 fractions/7 or 9 weeks). Post-mortem findings were analysed when available. Spirometric measurement of vital capacity, determination of diffusing capacity for carbon monoxide (DL) and alveolar volume with the single breath technique, and determination of regional distribution of lung perfusion by two different techniques, radiospirometry and gamma camera digital display following intravenous injection of 133Xe, were carried out before and at various times after the completion of irradiation. Of the physiologic parameters, only DL showed a significant decrease 6 as well as 9 months post-treatment (p less than 0.05). No difference between the two treatment schedules could be shown with regard to grade or time pattern of radiologic changes or decrease in DL. The findings suggest that measurement of DL may be of value in monitoring patients included in research protocols for radiation therapy of lung cancer as well as in selection of patients for this treatment.

Lack of protective effect of high-dose ipratropium on bronchoconstriction following exercise with cold air breathing in patients with mild asthma.

To evaluate the preventive effect of inhaled ipratropium powder on low-grade bronchoconstriction elicited by breathing cold air during exercise, we subjected 10 adult patients with mild asthma to four identical treadmill exercise tests. The temperature of inhaled air during exercise was -9 +/- 1 degree C. Sixty minutes before exercise, the patients inhaled either placebo or 0.2, 1, or 2 mg of ipratropium powder according to a cross-over, double-blind arrangement. The mean post-exercise fall from the post-treatment pre-exercise values in the four treatment groups was 14, 14, 16 and 16% for FEV1, and 59, 52, 52 and 55% for SGaw, respectively. We concluded that doses of ipratropium up to 20-50 times higher than those known to have a marked effect on resting bronchomotor tone in clinically stable asthma did not blunt the bronchoconstriction response following exercise with cold air breathing in our patients with mild asthma.

Combination of oxitropium bromide and salbutamol in the treatment of asthma with pressurized aerosols.

The bronchodilator effect of a combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide, given as pressurized aerosols, was compared to that of 200 and 400 micrograms of salbutamol in a controlled experiment on adult patients with asthma. The combined and the high dose salbutamol treatments were equally effective with respect to the response measured 60 minutes after administration, and both were significantly superior to the low dose salbutamol treatment. Bronchodilation persisted longer following the combined treatment than following the low or high dose salbutamol treatment. The results suggest that enhancement of the early bronchodilator response obtained by adding oxitropium bromide to a conventional dose of salbutamol in patients with stable asthma reflects suboptimal dosing of salbutamol rather than differences between the agents in mechanisms of action, whereas enhancement in duration of response is related also to the pharmacological characteristics of oxitropium bromide.

A controlled study on the effect of treatment with cromolyn sodium pressurized aerosol on bronchial reactivity in patients with asthma.

The effect of cromolyn sodium (CS) pressurized aerosol on bronchial hyperreactivity was assessed by comparison with placebo in a double-blind crossover study of 14 adult patients with clinically stable asthma. The trial was performed in a cold climate during the pollen-free winter months and the patient's risk of exposure to clinically relevant allergens was judged to be low. The dose was two puffs, each of 1 mg CS or placebo, four times daily over two successive 4-week periods, the order of treatment being decided by random allocation. No significant difference between treatments was observed in bronchial reactivity to histamine, determined as PC15. There was no difference between treatments with regard to symptoms, which were slight, or daily peak expiratory flow recordings, which showed minimal circadian variation. The results suggest that, although prolonged treatment with CS may decrease bronchial reactivity by reducing airway inflammation secondary to the assault of allergic stimuli, the drug probably has little or no effect on the basal bronchial reactivity in asthma.

Surgical treatment of chronic laryngeal stenosis secondary to vocal cord paralysis: pre and postoperative evaluation of ventilatory function.

Thirteen patients with chronic laryngeal stenosis were operated upon with total excision of stenotic scar tissue, enlargement of the lumen by sectioning the back and front wall of the larynx, and application of an indwelling Teflon prosthesis for 4 months. The stenosis was in many cases caused by long-standing recurrent paralysis complicated by attempted surgical correction of the stenosis. Following operation, the specific airway conductance increased in all patients (mean +/- SD pre and postoperative values 0.51 +/- 0.30 and 1.12 +/- 0.51 kPa-1.s-1, respectively). The FIV1/FVC ratio was determined in 9 patients and an increase was postoperatively noted in all of them (mean +/- SD pre and postoperative values 43 +/- 17 and 76 +/- 13%, respectively). The physiological findings confirmed the excellent clinical results of the treatment.

Comparison of ketotifen, disodium cromoglycate and placebo in the treatment of adult patients with mild extrinsic asthma.

Sixty-four patients with mild of moderate extrinsic asthma were treated with placebo for 1 month and thereafter with ketotifen (1 mg twice daily, orally), disodium cromoglycate (inhalation of 20 mg, four times daily), or placebo for 2 subsequent months. The trial was performed at four different centres and the treatments were compared using double-blind technique. We found no difference between the effect of ketotifen, disodium cromoglycate and placebo on the patients' daily measurements of evening peak expiratory flow, daily score values or respiratory symptoms of the number of salbutamol puffs required to control symptoms. There was no difference between the treatment groups with regard to the patients' estimates of changes in airway sensitivity to different non-specific stimuli: fumes, tobacco smoke, cold air, and exercise. The only significant effect of DSCG was a minor (4%) increase in the mean morning value for peak expiratory flow. The findings suggest that the addition of ketotifen or disodium cromoglycate to the regimen is unlikely to give further benefit in asthmatic patients, whose symptoms are reasonably well controlled by small doses of bronchodilating drugs.

[Treatment of chronic cicatricial laryngeal stenosis (author's transl)]. / Die Therapie chronisch-narbiger Larynxstenosen.

Eighty severe cases of chronic laryngeal stenosis in patients aged 1--78 years, where all other treatment had failed, were operated upon with laryngofissure of the front and back wall of the larynx followed by excision of the stenosis scar tissue. An endolaryngeal prosthesis was inserted and left in position for four months. The clinical result was good in 69 patients but, for various reasons, unsuccessful in eleven. The results of the treatment was also investigated by spirometry and body plethysmography. Contraindications for this operation are presented. The mean follow-up time was 6.9 years.

Slowly progressive bronchiolitis obliterans. A case report with detailed pulmonary function studies.

A case of idiopathic bronchiolitis obliterans in a 40-year-old man is presented. The chest radiograph showed miliary nodules, which on histological examination were found to consist of granulation tissue in and around bronchioles causing narrowing or obliteration of the airway lumen. The pulmonary function tests indicated a milk degree of airway obstruction, ventilation/perfusion inequality, hypoxemia which increased during exercise, and a well-preserved diffusion capacity suggesting absence of significant damage to the interstitium of the lung. Radiospirometry suggested that the functional derangement was most prominent in the lower parts of the lungs. Even though the inflammatory component was prominent no improvement was observed during steroid therapy. A history of respiratory symptoms for 20 years and a slight deterioration of the respiratory function over a follow-up period of 4 years suggested an unusually slow rate of progression of the disease.